Trials / Completed
CompletedNCT00233662
Safety and Tolerability of Repeat Courses of IM Alefacept
An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Repeat Courses of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Patients With Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether repeat courses of alefacept, administered intramuscularly, are safe when given to chronic plaque psoriasis patients who are receiving standard dermatology treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alefacept |
Timeline
- Start date
- 2002-12-01
- Completion
- 2005-12-01
- First posted
- 2005-10-06
- Last updated
- 2023-08-23
Locations
46 sites across 9 countries: United States, Austria, Canada, Denmark, France, Germany, Netherlands, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00233662. Inclusion in this directory is not an endorsement.